Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment
Chen JH, Lin YC, Chen CP, Cheng SH, Hu HC, Yeh HW, Shieh HT, Cheng CY
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2024-11
Abstract
The proportion of trough plasma concentration of dolutegravir (DTG) above protein adjusted 90 % inhibition concentration (IC90) (0.064 mg/L) was 98.1 % across all visits during the twelve doses of once-weekly rifapentine and isoniazid (3HP) in people with HIV (PWH). Furthermore, the participants maintained a high rate of HIV viral suppression (98 %) within 6 months after completing 3HP.
MeSH terms
- Humans
- HIV Infections
- Isoniazid
- Oxazines
- Piperazines
- Pyridones
- Heterocyclic Compounds, 3-Ring
- Rifampin
- HIV Integrase Inhibitors
- Antitubercular Agents
- Anti-HIV Agents
- Drug Monitoring
- Viral Load
- Adult
- Middle Aged
- Female
- Male
- Latent Tuberculosis
- Dolutegravir